H-Guard® will be evaluated for its safety and efficacy to address serious complement driven complications of haemodialysis GLASGOW, Scotland, Aug. 1, 2023 /PRNewswire/ — Invizius Limited (“Invizius”), a biotechnology company developing second generation therapies for a range of…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.